Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Amneal Pharmaceuticals Inc’s stock clocked out at $11.52, down -3.19% from its previous closing price of $11.9. In other words, the price has decreased by -$3.19 from its previous closing price. On the day, 1.21 million shares were traded. AMRX stock price reached its highest trading level at $11.96 during the session, while it also had its lowest trading level at $11.49.
Ratios:
To gain a deeper understanding of AMRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.35 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.51. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 2.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on June 06, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On February 24, 2025, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $9 to $12.
JP Morgan Upgraded its Underweight to Neutral on September 06, 2024, while the target price for the stock was maintained at $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 12 ’25 when NIKITA SHAH bought 131,856 shares for $11.92 per share.
Kiely John sold 32,000 shares of AMRX for $295,360 on Aug 27 ’25. The Director now owns 225,433 shares after completing the transaction at $9.23 per share. On Aug 27 ’25, another insider, Kiely John, who serves as the Director of the company, bought 32,000 shares for $9.18 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 3621460992 and an Enterprise Value of 6170992640. As of this moment, Amneal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 811.27, and their Forward P/E ratio for the next fiscal year is 12.22. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 31.02. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.23. Its current Enterprise Value per Revenue stands at 2.103 whereas that against EBITDA is 9.892.
Stock Price History:
The Beta on a monthly basis for AMRX is 1.37, which has changed by 0.40495872 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, AMRX has reached a high of $12.12, while it has fallen to a 52-week low of $6.68. The 50-Day Moving Average of the stock is 11.54%, while the 200-Day Moving Average is calculated to be 32.88%.
Shares Statistics:
It appears that AMRX traded 1.71M shares on average per day over the past three months and 2323750 shares per day over the past ten days. A total of 314.31M shares are outstanding, with a floating share count of 156.59M. Insiders hold about 50.88% of the company’s shares, while institutions hold 42.81% stake in the company. Shares short for AMRX as of 1761868800 were 5577526 with a Short Ratio of 3.27, compared to 1759190400 on 5694704. Therefore, it implies a Short% of Shares Outstanding of 5577526 and a Short% of Float of 2.75.
Earnings Estimates
. The current market rating for Amneal Pharmaceuticals Inc (AMRX) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.19, with high estimates of $0.21 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.82 and $0.78 for the fiscal current year, implying an average EPS of $0.8. EPS for the following year is $0.94, with 4.0 analysts recommending between $1.03 and $0.89.
Revenue Estimates
In. The current quarter, 4 analysts expect revenue to total $808.14M. It ranges from a high estimate of $822.7M to a low estimate of $790.11M. As of. The current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $730.52MFor the next quarter, 4 analysts are estimating revenue of $741.79M. There is a high estimate of $748.71M for the next quarter, whereas the lowest estimate is $728.7M.
A total of 4 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $3.03B, while the lowest revenue estimate was $2.99B, resulting in an average revenue estimate of $3.01B. In the same quarter a year ago, actual revenue was $2.79BBased on 4 analysts’ estimates, the company’s revenue will be $3.21B in the next fiscal year. The high estimate is $3.23B and the low estimate is $3.18B.
